BeiGene CEO on Coronavirus Impact, China Biopharma, Product Pipeline

The transcript discusses the impact of COVID-19 on a global company's operations, highlighting remote work and challenges in clinical trials. The company remains focused on cancer therapies but explores potential COVID-19 treatments. Market demand for oncology products is affected, and financials show the company is still in an investment phase. A product suspension due to manufacturing issues is addressed, emphasizing the company's commitment to affordable medicines.

How has the demand for oncology products changed during the pandemic?

What role does the company see itself playing in the development of affordable medicines?

Can you explain the situation regarding the suspension of the product ABRAXANE in China?